Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study

BACKGROUND: To compare the cardiovascular event risk in type 2 diabetes patients newly receiving dapagliflozin vs. empagliflozin. METHODS: We conducted a retrospective cohort study by analyzing a multi-institutional electronic medical records database (Chang Gung Research Database) in Taiwan and inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Shih-Chieh, Chang, Kai-Cheng, Hung, Ming-Jui, Yang, Ning-I, Chan, Yuk-Ying, Chen, Hui-Yu, Kao Yang, Yea-Huei, Lai, Edward Chia-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760106/
https://www.ncbi.nlm.nih.gov/pubmed/31551068
http://dx.doi.org/10.1186/s12933-019-0919-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760106/
https://www.ncbi.nlm.nih.gov/pubmed/31551068
http://dx.doi.org/10.1186/s12933-019-0919-9

Ejemplares similares